Enobia Pharma

Français
About Enobia \| Technology \| Programs \| Corporate \| News \| Contact

October 2nd, 2008
Enobia to present at BioContact - Quebec City
More Info

September 25th, 2008
Enobia to present at BioProcess International Conference & Exhibition – Anaheim, California
More Info

September 24th, 2008
Enobia to present at UBS Global Life Sciences Conference – New York City

September 13th, 2008
Enobia to present at ASBMR 30th Annual Meeting – Montreal, Quebec
More Info

June 11th, 2009
Enobia Announces Positive Interim Clinical Results with ENB-0040
Download the PDF

June 11th, 2009<
Shriners Hospitals for Children's Dr. Michael Whyte Presents First Efficacy and Safety Results of Targeted Enzyme Replacement Therapy in Patients With Rare Genetic Bone Disease
Download the PDF

May 19th, 2009
Enobia Pharma's ENB-0040 receives FDA fast track designation
Download the PDF

March 6th, 2009
Winnipeg Regional Health Authority Announces baby Amy homeward-bound following five months on life saving experimental treatment at children’s hospital
Download the PDF

March 3rd, 2009
Enobia completes target enrollment in clinical trial for infantile Hypophosphatasia
Download the PDF

December 1st, 2008
Enobia initiates infantile enzyme replacement trial for rare bone disease
Download the PDF

September 22th, 2008
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Download the PDF

September 19th, 2008
Enobia Pharma receives FDA orphan drug designation for Hypophosphatasia product candidate ENB-0040
Download the PDF

September 15th, 2008
Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Download the PDF

August 20th, 2008
Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
Download the PDF
Download the PDF (US)

September 10th, 2007
Enobia Pharma Raises $40.1M Series B Financing
Download the PDF

July 25, 2007
Enobia Pharma announces an agreement with Laureate Pharma for the production of its fusion protein which Enobia is developing for the treatment of hypophophatasia
Download the PDF

July 2007
Enobia Pharma announces new data on its hypophosphatasia program to be presented September 19, 2007 at the Annual Meeting of the ASBMR in Hawaii

Enobia is dedicated to treating rare and severe genetic bone-growth disorders for which there are currently no approved drug therapy.

Enobia focuses on the development of therapeutics for the treatment of severe orphan disorders affecting the bone, where no approved therapy exits. These disorders result from a well characterized imbalance in specific enzymes resulting in impaired bone growth.

Using patented bone-targeting technology Enobia’s lead program is the development of Enzyme Replacement Therapy for hypophosphatasia, a disorder of bone mineralization.

home | technology | programs | corporate | news | contact
Copyright (c) 2006, Enobia pharma inc. All rights reserved. Website design by NRJ Design